Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly

What Was Tested

Researchers studied Somatostatin and Lanreotide in this clinical trial, phase iii publication.

Intention-to-treat analysis was performed to determine the proportion of patients with normalized age-adjusted IGF-I levels at study end.

Why It Was Studied

An essential criterion for control of acromegaly is normalization of IGF-I levels.

Somatostatin analogues act to suppress IGF-I and GH levels.

Who Took Part

By PubMed's age tags, the people studied were teenagers, young adults, adults, middle-aged adults, older adults and people over 80, both men and women.

Patients with active acromegaly (IGF-I levels > 1.3 times upper limit of age-adjusted normal range) were recruited.

How the Study Was Run

The design is described as open-label and multicenter.

Everyone knew when Somatostatin was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Running at several centres spread the Somatostatin study over different clinics and patient groups.

Open-label, multicentre, phase III, 48-week trial.

Secondary evaluations included GH levels, clinical acromegaly signs and safety.

What Was Measured

An essential criterion for control of acromegaly is normalization of IGF-I levels.

Somatostatin analogues act to suppress IGF-I and GH levels.

The subject headings attached to it are Acromegaly, Antineoplastic Agents, Gels, Human Growth Hormone, Insulin-Like Growth Factor I, Peptides, Cyclic and Somatostatin.

What This Means in Plain Language

The paper is an open-label and multicenter study of Somatostatin and Lanreotide.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2008 (Clinical endocrinology), a journal based in England.

More context: the Somatostatin compound page and the Lanreotide compound page.